期刊
CELL
卷 161, 期 5, 页码 1215-1228出版社
CELL PRESS
DOI: 10.1016/j.cell.2015.05.001
关键词
-
资金
- Stand Up To Cancer-Prostate Cancer Foundation Prostate Dream Team Translational Cancer Research Grant
- NIH: Clinical Sequencing Exploratory Research (CSER) [UM1HG006508]
- NIH: Early Detection Research Network grant [UO1 CA111275]
- NIH: Prostate SPORE [P50 CA186786, P50 CA092629, P50 CA90381, P50 CA097186, P01 CA163227, R01 CA116337, R01 CA155169, R01 CA092629]
- DoD [W81XWH-09-1-0147, DOD PC121341, PC131820]
- Starr Cancer Consortium
- Damon Runyon Cancer Research Foundation [CI-67-13]
- PCF Young Investigator Award
- NIH [1K08CA188615]
- Prostate Cancer Foundation Young Investigator Awards
- Movember Foundation
- ECMC network from Cancer Research UK
- Department of Health in the UK
- BRC grant
- Prostate Cancer UK, PCF
- MRC [MR/M003272/1] Funding Source: UKRI
- Cancer Research UK [13239] Funding Source: researchfish
- Medical Research Council [MR/M003272/1] Funding Source: researchfish
- National Institute for Health Research [CL-2008-22-001] Funding Source: researchfish
- Prostate Cancer UK [PG12-49, CEO13_2-002] Funding Source: researchfish
Toward development of a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we established a multi-institutional clinical sequencing infrastructure to conduct prospective whole-exome and transcriptome sequencing of bone or soft tissue tumor biopsies from a cohort of 150 mCRPC affected individuals. Aberrations of AR, ETS genes, TP53, and PTEN were frequent (40%-60% of cases), with TP53 and AR alterations enriched in mCRPC compared to primary prostate cancer. We identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, beta-catenin, and ZBTB16/PLZF. Moreover, aberrations of BRCA2, BRCA1, and ATM were observed at substantially higher frequencies (19.3% overall) compared to those in primary prostate cancers. 89% of affected individuals harbored a clinically actionable aberration, including 62.7% with aberrations in AR, 65% in other cancer-related genes, and 8% with actionable pathogenic germline alterations. This cohort study provides clinically actionable information that could impact treatment decisions for these affected individuals.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据